Egypt’s Chamber of Pharmaceutical Industry announced exceptional results achieved by the pharmaceutical sector in the export index, with the value of Egyptian pharmaceutical exports to African markets rising 34% during the first quarter of 2026 to reach 680 million dollars, compared to 507 million dollars in the corresponding period of the previous year. This increase comes amid growing demand for high-quality, competitively priced medicines in emerging African markets, a competitive advantage the Egyptian pharmaceutical industry possesses in abundance.
The Chamber revealed the signing of new marketing and distribution agreements with the health ministries of 15 African countries, including Nigeria, Ethiopia, Kenya, Tanzania, Ghana, Angola, Mozambique, and a number of West African nations. These agreements focus on supplying generic medicines and treatments for diseases endemic to Africa such as malaria, tuberculosis, and neglected tropical diseases that afflict millions of people across the continent. Some agreements also include the establishment of regional distribution warehouses in partnership with local partners.
Egypt’s Ministry of Health expressed strong support for this export orientation, regarding it as part of Egypt’s strategy to become one of the continent’s principal pharmaceutical suppliers. The minister noted that Egypt possesses 130 pharmaceutical factories operating according to international Good Manufacturing Practices, with 65% holding accreditation from the European Medicines Agency or the US FDA, a fact that strengthens African markets’ confidence in Egyptian quality.
On the challenges front, industry experts noted that fierce competition from cheaper Indian and Chinese medicines represents a genuine obstacle requiring the development of intelligent pricing strategies, alongside the need to facilitate the registration of Egyptian medicines in African markets, whose regulatory procedures tend to be complex and time-consuming. Experts also call on the government to enhance diplomatic support to remove regulatory and customs obstacles in target countries.
This export orientation reflects a comprehensive Egyptian vision for developing the pharmaceutical industry as a high-value-added sector and an instrument of soft power in Egypt’s African relations. In light of the major transformations in global pharmaceutical supply chains in the post-COVID era, Egypt finds before it a precious opportunity to cement its position as a trusted and viable alternative within the African and global pharmaceutical ecosystem alike.